Normothermic <i>ex vivo</i> heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation.

Xu, Liwei; Zeng, Zifeng; Niu, Chuanjie; Liu, Deshen; Lin, Shaoyan; Liu, Xiu; Szabó, Gábor; Lu, Jun; Zheng, Shaoyi; Zhou, Pengyu

Normothermic ex vivo heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation.

Xu, Liwei; Zeng, Zifeng; Niu, Chuanjie; Liu, Deshen; Lin, Shaoyan; Liu, Xiu; Szabó, Gábor; Lu, Jun; Zheng, Shaoyi; Zhou, Pengyu.

Afiliação

Xu L; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zeng Z; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Niu C; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liu D; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Lin S; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liu X; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Szabó G; Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany.
Lu J; Department of Cardiac Surgery, University of Halle (Saale), Halle, Germany.
Zheng S; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhou P; Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.